United Kingdom· GB-APID-45285311000001102
Hympavzi 150mg/1ml solution for injection pre-filled pens
A marstacimab product containing marstacimab, registered in United Kingdom by Pfizer Ltd. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Marstacimab is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BX11 (marstacimab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Marstacimab · ATC B02BX11
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Marstacimab
- Manufacturer
- Pfizer Ltd
- Country
- United Kingdom (GB)
- ATC code
- B02BX11
- ATC class
- Marstacimab
- Defined daily dose
- 21 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5415062126301
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Marstacimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaHYMPAVZIPfizer Europe MA EEIG, Bruxelles
- BelgiumHympavzi 150 mgPfizer Europe MA
- IcelandHympavziPfizer Europe MA EEIG*
- SwedenHympavzi 150 mg Injektionsvätska, lösning i förfylld injektionspennaPfizer Europe MA EEIG
- SpainHYMPAVZI 150 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAPfizer Europe Ma Eeig
- NorwayHympavziPfizer Europe MA EEIG
- United StatesHYMPAVZIPfizer Laboratories Div Pfizer Inc
- IrelandHympavzi 150 mg solution for injection in pre-filled penPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hympavzi
- Liechtenstein · Hympavzi
- Norway · Hympavzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bea5551d-7514-41e8-9e15-e2c13a6f96cf GET /v1/drugs/bea5551d-7514-41e8-9e15-e2c13a6f96cf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45285311000001102",
"desc": "Hympavzi 150mg/1ml solution for injection pre-filled pens (Pfizer Ltd)",
"form": "Solution for injection",
"vpid": "45294311000001102",
"source": "dmd",
"vtm_id": "45291711000001101",
"strength": "150 mg",
"substance": "Marstacimab",
"ingredient": "Marstacimab",
"supplier_code": "2082201000001106"
}See everything about marstacimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.